FDA approves Cordis' rapid-exchange heparin-coated stent:
This article was originally published in Clinica
Executive Summary
The US FDA has approved Cordis' heparin-coated coronary stent for use on a rapid-exchange delivery system, called Raptorail. The Bx Velocity coronary stent with HEPACOAT was first approved for over-the-wire delivery in November 2000, when it became the first drug-coated stent to receive regulatory approval, says Cordis, a Johnson & Johnson firm.
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.